Verigraft AB
Gothenburg
About Verigraft AB
Verigraft AB is a biotech company that generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s technology does not require immunosuppression. With this unique, patented and improved alternative to existing treatments, VERIGRAFT strives to deliver a life changing impact to patients and provide major benefits for hospitals, healthcare providers and society – globally. VERIGRAFT’s personalized tissue-engineered vein (P-TEV) has gone through preclinical development at the company. Safety data from large animals has been generated. Clinical proof-of-concept in humans exists. The product is planned to enter clinical development within 6 months.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $16.3M
- Last round: Undisclosed (Mar 2026)
- Website: verigraft.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/verigraft-ab-9546 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.